Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

NCT04225923 is registered in ClinicalTrials.gov with Nobelpharma as lead sponsor.

NCT NCT04225923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04225923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Lead sponsor
Nobelpharma
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2020
Completion date
February 8, 2023
Enrollment
87 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

cytomegalovirus disease